Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice

Journal of Sexual Medicine

Volumn 11, Issue 11, 2014, Pages 2661-2670

  Silva, Fábio H ^a   Leiria, Luiz O ^a   Alexandre, Eduardo C ^a   Davel, Ana Paula C ^a   Mónica, Fabíola Z ^a   De Nucci, Gilberto ^a   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Corpus cavernosum; Cyclic GMP; Erectile dysfunction; Intracavernous pressure; Obesity; Oxidative stress; Reactive oxygen species

Indexed keywords

ACETYLCHOLINE; BAY 60 2770; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 4-(((4-CARBOXYBUTYL) (2- (5-FLUORO-2-((4'-(TRIFLUOROMETHYL) BIPHENYL-4-YL)METHOXY)PHENYL)ETHYL) AMINO)METHYL)BENZOIC ACID; BENZOIC ACID DERIVATIVE; BIPHENYL DERIVATIVE; CELL RECEPTOR; ENZYME ACTIVATOR; FLUORINATED HYDROCARBON; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; DISEASE MODEL; ELECTROSTIMULATION; ERECTILE DYSFUNCTION; FOOD INTAKE; IN VITRO STUDY; INTRACAVERNOSAL PRESSURE; LIPID DIET; MALE; MALE GENITAL TRACT PARAMETERS; MOUSE; MUSCLE RELAXATION; NERVE STIMULATION; NONHUMAN; OBESITY; PENIS ERECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT OUTCOME; UPREGULATION; ADVERSE EFFECTS; AGONISTS; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PENIS; VASCULARIZATION;

ANIMALS; BENZOATES; BIPHENYL COMPOUNDS; CYCLIC GMP; DIET, HIGH-FAT; ENZYME ACTIVATORS; ERECTILE DYSFUNCTION; GUANYLATE CYCLASE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PENILE ERECTION; PENIS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; UP-REGULATION;

EID: 84911482873     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12682     Document Type: Article

References (46)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Chung WS, Sohn JH, Park YY. Is obesity an underlying factor in erectile dysfunction? Eur Urol 1999;36:68-70.
3. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: Can lifestyle changes modify risk? Urology 2000;56:302-306.
4. Chao JK, Hwang TI, Ma MC, Kuo WH, Liu JH, Chen YP, Lin YC. A survey of obesity and erectile dysfunction of men conscripted into the military in Taiwan. J Sex Med 2011;8:1156-1163.
5. Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: A randomized controlled trial. JAMA 2004;291:2978-2984.
6. Garcia MM, Fandel TM, Lin G, Shindel AW, Banie L, Lin CS, Lue TF. Treatment of erectile dysfunction in the obese type 2 diabetic ZDF rat with adipose tissue-derived stem cells. J Sex Med 2010;7:89-98.
7. Luttrell IP, Swee M, Starcher B, Parks WC, Chitaley K. Erectile dysfunction in the type II diabetic db/db mouse: Impaired venoocclusion with altered cavernosal vasoreactivity and matrix. Am J Physiol Heart Circ Physiol 2008;294:H2204-2211.
8. Carneiro FS, Giachini FR, Lima VV, Carneiro ZN, Leite R, Inscho EW, Tostes RC, Webb RC. Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse. J Sex Med 2008;5:1156-1166.
9. Toque HA, da Silva FH, Calixto MC, Lintomen L, Schenka AA, Saad MJ, Zanesco A, Antunes E. High-fat diet associated with obesity induces impairment of mouse corpus cavernosum responses. BJU Int 2011;107:1628-1634.
10. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 2011;63:811-859.
11. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, Durante-Montiel I, Sánchez-Rivera G, Valadez-Vega C, Morales-González JA. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011;12:3117-3132.
12. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561.
13. Sayed N, Baskaran P, Ma X, van den Akker F, Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci U S A 2007;104:12312-12317.
14. Jeremy JY, Jones RA, Koupparis AJ, Hotston M, Persad R, Angelini GD, Shukla N. Reactive oxygen species and erectile dysfunction: Possible role of NADPH oxidase. Int J Impot Res 2007;19:265-280.
15. Musicki B, Liu T, Lagoda GA, Strong TD, Sezen SF, Johnson JM, Burnett AL. Hypercholesterolemia-induced erectile dysfunction: Endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med 2010;7:3023-3032.
16. Kots AY, Bian K, Murad F. Nitric oxide and cyclic GMP signaling pathway as a focus for drug development. Curr Med Chem 2011;18:3299-3305.
17. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006;111:400-423.
18. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-215.
19. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate ciclase stimulators. Handb Exp Pharmacol 2009;191:277-308.
20. Gur S, Kadowitz PJ, Hellstrom WJ. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Des 2010;16:1619-1633.
21. Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: A stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003;61:464-467.
22. Baracat JS, Teixeira CE, Okuyama CE, Priviero FB, Faro R, Antunes E, De Nucci G. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 2003;477:163-169.
23. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M, Stasch JP, Schmidt HH, Müller-Esterl W. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate ciclase from proteasomal degradation. Circ Res 2009;105:33-41.
24. Jones AW, Durante WJ, Korthuis RJ. Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation. J Pharmacol Exp Ther 2010;335:85-91.
25. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Harter M, Hahn M, Keim Y, Wunder F, Stasch JP. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 2008;58:71-80.
26. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, Stasch JP. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 2009;157:781-795.
27. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, Roussos C, Papapetropoulos A. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:1763-1771.
28. Kumar V, Martin F, Hahn MG, Schaefer M, Stamler JS, Stasch JP, van den Akker F. Insights into BAY 60-2770 Activation and S-Nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous Nostoc H-NOX domain complexes. Biochemistry 2013;52:3601-3608.
29. Lasker GF, Pankey EA, Frink TJ, Zeitzer JR, Walter KA, Kadowitz PJ. The sGC activator BAY 60-2770 has potent erectile activity in the rat. Am J Physiol Heart Circ Physiol 2013;304:H1670-1679.
30. Alexandre EC, Leiria LO, Silva FH, Mendes-Silverio CB, Calmasini FB, Davel AP, Monica FZ, De Nucci G, Antunes E. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: Reversal by the sGC activator BAY 60-2770. J Pharmacol Exp Ther 2014;349:2-9.
31. Leiria LO, Silva FH, Davel APC, Alexandre EC, Calixto MC, De Nucci G, Mónica FZ, Antunes E. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice. J Urol 2014;191:539-547.
32. Li M, Zhuan L, Wang T, Rao K, Yang J, Yang J, Quan W, Liu J, Ye Z. Apocynin improves erectile function in diabetic rats through regulation of NADPH oxidase expression. J Sex Med 2012;9:3041-3050.
33. Silva FH, Mónica FZ, Báu FR, Brugnerotto AF, Priviero FB, Toque HA, Antunes E. Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: Prevention by antioxidant therapy. J Sex Med 2013;10:960-971.
34. Claudino MA, Franco-Penteado CF, Priviero FB, Camargo EA, Teixeira SA, Muscará MN, De Nucci G, Zanesco A, Antunes E. Upregulation of gp91phox subunit of NAD(P)H oxidase contributes to erectile dysfunction caused by long-term nitric oxide inhibition in rats: Reversion by regular physical training. Urology 2010;75:961-967.
35. Muzaffar S, Shukla N, Srivastava A, Angelini GD, Jeremy JY. Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 2005;146:109-117.
36. Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005;96:423-427.
37. Radovits T, Korkmaz S, Miesel-Gröschel C, Seidel B, Stasch JP, Merkely B, Karck M, Szabó G. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg 2011;39:248-255.
38. Schmidt HH, Schmidt P, Stasch JP. NO and haem-independent soluble guanylyl cyclase activators. Hand Exp Pharmacol 2009;191:309-339.
39. Kagota S, Tamashiro A, Yamaguchi Y, Sugiura R, Kuno T, Nakamura K, Kunitomo M. Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats. Br J Pharmacol 2001;134:737-744.
40. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, Schmidt HH. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004;101:16671-16676.
41. Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, Mittal M, Fuchs B, Medebach T, Dumitrascu R, Eickels MV, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 2009;297:L658-665.
42. Pankey EA, Bhartiya M, Badejo AM, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl ciclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol 2011;300:792-802.
43. Selemidis S, Dusting GJ, Peshavariya H, Kemp-Harper BK, Drummond GR. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res 2007;75:349-358.
44. Teixeira CE, Priviero FB, Webb RC. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3, 4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl ciclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice. J Pharmacol Exp Ther 2007;322:1093-1102.
45. Stephens RS, Servinsky LE, Rentsendorj O, Kolb TM, Pfeifer A, Pearse DB. Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase. Am J Physiol Cell Physiol 2014;306:C559-569.
46. Stephens RS, Rentsendorj O, Servinsky LE, Moldobaeva A, Damico R, Pearse DB. cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2010;299:L323-333.